Tumour biopsies from a phase I clinical trial, where a patient was treated with 4 weeks of vemurafenib followed by 4 cycles of anti-CTLA4 antibody ipilimumab [29], demonstrated an influx of CD8 + T-cells and increased CD8 + to T-regulatory cell ratio at day 8 [14]. Here, CD8A is linked to neoplasm.